News Releases

  Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value Strong balance sheet of $161 million in cash, cash equivalents and marketable securities as of June 30, 2022 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug.

Company intends to seek a partner for further development of Vicineum Sesen Bio continues to focus on the assessment of potential strategic alternatives CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 18, 2022-- Sesen Bio (Nasdaq: SESN ) today announced that it has made the strategic decision to

Strong balance sheet of $170 million in cash and cash equivalents as of March 31, 2022 , expected to fund current operating plan into the fourth quarter of 2024 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2022-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has initiated a process to review strategic alternatives with the goal of

Participated in productive CMC and Clinical Type A Meetings with the FDA in the fourth quarter Type C Meeting with the FDA planned for March 28, 2022 Strong balance sheet with $163M in cash and cash equivalents as of December 31, 2021 expected to fund current operating plan into 2024 CAMBRIDGE,

Minori Rosales , M.D., Ph.D. Brings Over 15 Years of Clinical Experience Stephanie Vigue to Support Company’s Mission with Broad Corporate Finance Expertise CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 10, 2022-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein